Phar­ma gi­ants back a leader in vir­tu­al clin­i­cal tri­als as Covid-19 blights sites

While tra­di­tion­al tri­al sites are un­der enor­mous pres­sure amid the Covid-19 pan­dem­ic, 3 phar­ma gi­ants con­tin­ue to back a leader in vir­tu­al clin­i­cal tri­als.

Los An­ge­les-based Sci­ence 37 closed a $40 mil­lion fund­ing round on Fri­day, with in­vest­ments from No­var­tis, Am­gen and Sanofi Ven­tures. Lux Cap­i­tal, Red­mile Group and PPD led the round, and LifeSci Ven­tures and Mubadala Ven­tures joined in for the first time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER